Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Turning Point ROS1/TRK Inhibitor Repotrectinib Could Stand Out On Durability

Executive Summary

The drug showed a high durability of response in ROS1-positive NSCLC patients, a factor that could give it significant differentiation compared with approved agents.

You may also be interested in...



It Takes A Village: Roche’s India Rare Disease Approach, Crowdfunding Support

Roche Pharma India CEO and managing director, V Simpson Emmanuel, outlines the company's multi-forked approach, including collaborating with a crowdfunding platform, to move the access and treatment needle for Evrysdi in India. The Swiss firm, along with industry associations, also suggests the need for a formal accelerated regulatory pathway in India for rare diseases.

Keeping Track: A Quintet Of Novel Approvals

The latest drug development news and highlights from our US FDA Performance Tracker. 

Foghorn’s AML/MDS Program Likely Still A Go Despite Partial Hold

The company’s Phase I study of FHD-286 had a patient death due to differentiation syndrome, but that’s a known adverse event in multiple approved AML drugs.

Topics

Related Companies

UsernamePublicRestriction

Register

SC146229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel